Today's guest post comes from Gerard Rivera, Co-Founder & CEO at RIS Rx. Gerard Rivera examines how copay programs and real-time gross-to-net (GTN) revenue protection can work together to support patient access and program performance. He highlights how simpler program design, timely data, and responsive action can help manufacturers manage affordability programs while preserving patient experience. To learn more about RIS Rx's gross-to-net (GTN) revenue protection solution, get a custom GTN assessment from RIS Rx. Read on for Gerard's insights. Read more » © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

By Bryce Platt, PharmD PBMs outside the Big Three still earn higher customer satisfaction ratings, but their lead has nearly disappeared. Meanwhile, plan sponsors are inviting alternatives into their RFPs, and some are changing vendors. Research on 2027 benefits planning suggests the shopping will continue. That combination points to a new test for alternative PBMs—one where they have to turn their pitch into value that plan sponsors continue to see after they sign a contract. Below we examine the shrinking satisfaction advantage, the choices plan sponsors are considering for 2027, and why the grass may not always be greener on the alternative PBM side. Drug Channels Leadership Forum 2027 The Drug Channels Leadership Forum agenda is now available! Explore the agenda and request your invitation to this invite-only gathering of senior leaders from across the drug channel ecosystem. You must request an invitation to be considered for attendance. Read more » © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.